Logo image of PAND

Pandion Therapeutics Inc (PAND) Stock Price, Quote, News and Overview

NASDAQ:PAND - Nasdaq -

60.05  +0.13 (+0.22%)

After market: 60.05 0 (0%)

PAND Quote, Performance and Key Statistics

Pandion Therapeutics Inc

NASDAQ:PAND (3/31/2021, 8:12:53 PM)

After market: 60.05 0 (0%)

60.05

+0.13 (+0.22%)

Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
Statistics
52 Week High62.9
52 Week Low10.28
Market Cap1.77B
Shares29.52M
FloatN/A
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-11 2022-03-11/amc
IPON/A N/A


PAND short term performance overview.The bars show the price performance of PAND in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300 400

PAND long term performance overview.The bars show the price performance of PAND in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of PAND is 60.05 null. In the past month the price decreased by -2.56%.

Pandion Therapeutics Inc / PAND Daily stock chart

About PAND

Company Profile

Pandion Therapeutics Inc. is a biotechnology company. It focuses on developing modular proteins, antibodies and bispecifics for the treatment of autoimmune and inflammatory diseases. Pandion Therapeutics Inc. is based in North Cambridge, United States.

Company Info

Pandion Therapeutics Inc

134 COOLIDGE AVENUE 2ND FLOOR

WATERTOWN MA 02472

CEO: Rahul Kakkar

Phone: 617-393-5925

Pandion Therapeutics Inc / PAND FAQ

What is the stock price of Pandion Therapeutics Inc today?

The current stock price of PAND is 60.05 null. The price increased by 0.22% in the last trading session.


What is the ticker symbol for Pandion Therapeutics Inc stock?

The exchange symbol of Pandion Therapeutics Inc is PAND and it is listed on the Nasdaq exchange.


On which exchange is PAND stock listed?

PAND stock is listed on the Nasdaq exchange.


What is Pandion Therapeutics Inc worth?

Pandion Therapeutics Inc (PAND) has a market capitalization of 1.77B null. This makes PAND a Small Cap stock.


What are the support and resistance levels for Pandion Therapeutics Inc (PAND) stock?

Pandion Therapeutics Inc (PAND) has a support level at 60.02 and a resistance level at 61.64. Check the full technical report for a detailed analysis of PAND support and resistance levels.


Should I buy Pandion Therapeutics Inc (PAND) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Pandion Therapeutics Inc (PAND) stock pay dividends?

PAND does not pay a dividend.


When does Pandion Therapeutics Inc (PAND) report earnings?

Pandion Therapeutics Inc (PAND) will report earnings on 2022-03-11, after the market close.


What is the Price/Earnings (PE) ratio of Pandion Therapeutics Inc (PAND)?

Pandion Therapeutics Inc (PAND) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.81).


PAND Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to PAND.


Chartmill TA Rating
Chartmill Setup Rating

PAND Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to PAND. PAND may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PAND Financial Highlights

Over the last trailing twelve months PAND reported a non-GAAP Earnings per Share(EPS) of -2.8116. The EPS increased by 86.71% compared to the year before.


Industry RankSector Rank
PM (TTM) -434.05%
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)86.71%
Revenue 1Y (TTM)807.86%

PAND Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 73% to PAND. The Buy consensus is the average rating of analysts ratings from 3 analysts.


Ownership
Inst OwnersN/A
Ins Owners19.35%
Short Float %N/A
Short RatioN/A
Analysts
Analysts73.4
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A